学术探索
学术期刊
学术作者
新闻热点
数据分析
智能评审

Gene therapy for melanoma in humans

被引：6
作者：
Gutzmer, R
Guerry, D
机构：
[1] Univ Penn, Sch Med, Inst Human Gene Therapy, Div Hematol Oncol, Philadelphia, PA 19104 USA
[2] Hosp Univ Penn, Philadelphia, PA 19104 USA
[3] Univ Penn, Ctr Comprehens Canc, Melanoma Program, Philadelphia, PA 19104 USA
来源：
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 1998年 / 12卷 / 03期
关键词：
D O I：
10.1016/S0889-8588(05)70006-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 [肿瘤学];
摘要：
As melanoma evolves, it interacts with the immune system. Based on this immunobiology, there are now a number of rationally designed attempts to develop genetically modified melanoma; vaccines. This article outlines immunologic and other strategies in gene therapy for melanoma and provides an overview of current clinical trials.
引用
收藏
页码：519 / +
页数：21
相关论文
共 137 条
[1]
AbdelWahab Z, 1997, CANCER, V80, P401, DOI 10.1002/(SICI)1097-0142(19970801)80:3<401::AID-CNCR8>3.0.CO
[2]
2-U
[3]
In vivo antitumor effect of cytotoxic T lymphocytes engineered to produce interferon-gamma by adenovirus-mediated genetic transduction [J].
Abe, J ;
Wakimoto, H ;
Tsunoda, R ;
Okabe, S ;
Yoshida, Y ;
Aoyagi, M ;
Hirakawa, K ;
Hamada, H .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1996, 218 (01) :164-170
[4]
ALEXANDER MA, 1989, J IMMUNOL, V142, P4070
[5]
Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells [J].
Arienti, F ;
SuleSuso, J ;
Belli, F ;
Mascheroni, L ;
Rivoltini, L ;
Melani, C ;
Maio, M ;
Cascinelli, N ;
Colombo, MP ;
Parmiani, G .
HUMAN GENE THERAPY, 1996, 7 (16) :1955-1963
[6]
Armstrong CA, 1996, CANCER RES, V56, P2191
[7]
BECKER JC, 1993, J IMMUNOL, V151, P7224
[8]
TUMOR ESCAPE MECHANISMS FROM IMMUNOSURVEILLANCE - INDUCTION OF UNRESPONSIVENESS IN A SPECIFIC MHC-RESTRICTED CD4+ HUMAN T-CELL CLONE BY THE AUTOLOGOUS MHC CLASS-II+ MELANOMA [J].
BECKER, JC ;
BRABLETZ, T ;
CZERNY, C ;
TERMEER, C ;
BROCKER, EB .
INTERNATIONAL IMMUNOLOGY, 1993, 5 (12) :1501-1508
[9]
Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: Evaluation of efficacy and tolerability [J].
Belli, F ;
Arienti, F ;
SuleSuso, J ;
Clemente, C ;
Mascheroni, L ;
Cattelan, A ;
Sanantonio, C ;
Gallino, GF ;
Melani, C ;
Rao, S ;
Colombo, MP ;
Maio, M ;
Cascinelli, N ;
Parmiani, G .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1997, 44 (04) :197-203
[10]
Bennicelli J L, 1993, Exp Dermatol, V2, P186, DOI 10.1111/j.1600-0625.1993.tb00031.x
12345678910